Pamela Scott - Potent, orally active aldose reductase inhibitors related to zopolrestat:

Document created by Pamela Scott on Aug 22, 2014
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

  Journal of Medicinal Chemistry (1992), 35(3), 457-65

  Abstract:

  A broad structure-activity program was undertaken in search of   effective
       surrogates for the key benzothiazole   side chain of the potent aldose
       reductase inhibitor, zopolrestat.    A structure-driven approach was
       pursued, which spanned exploration of   three areas: (1) 5/6 fused
       heterocycles, such as benzoxazole,   benzothiophene, benzofuran, and
       imidazopyridine; (2) 5-membered   heterocycles, including oxadiazole,
       oxazole, thiazole, and thiadiazole, with   pendant aryl groups, and (3)
       thioanilide as a formal equiv. of   benzothiazole.  Several benzoxazole- and
       1,2,4-oxadiazole-derived analogs were   found to be potent inhibitors of
       aldose reductase from human placenta and   were orally active in preventing
       sorbitol accumulation in rat sciatic   nerve, in an acute test of diabetic
       complications.  Phthalazineacetic   acid I was the best of the benzoxazole
       series ([C50 = 3.2 .times. 10-9M); it   suppressed accumulation of sorbitol
       in rat sciatic nerve by 78% at an oral   dose of 10 mg/kg.  Oxadiazolyl
       deriv. II with IC50 < 1.0 .times.   10-8M, caused a 69% redn. in sorbitol
       accumulation in rat sciatic nerve at an   oral dose of 25 mg/kg.  The
       thioanilide side chain features in III   proved to be an effective surrogate
       for benzothiazole.  III was highly   potent in vitro (IC50 = 5.2 .times.
       10-8M) but did not show oral activity   when tested at 100 mg/kg.  Addnl.
       structure-activity relationships   encompassing a variety of heterocyclic
       side chains are discussed.

  Address (URL): http://

 

Attachments

    Outcomes